⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INAB News
IN8bio, Inc. Common Stock
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
globenewswire.com
INAB
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
globenewswire.com
INAB
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
globenewswire.com
INAB
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
globenewswire.com
INAB